HK1105421A1 - Il-1 antagonist formulations il-1 - Google Patents

Il-1 antagonist formulations il-1

Info

Publication number
HK1105421A1
HK1105421A1 HK07110745.0A HK07110745A HK1105421A1 HK 1105421 A1 HK1105421 A1 HK 1105421A1 HK 07110745 A HK07110745 A HK 07110745A HK 1105421 A1 HK1105421 A1 HK 1105421A1
Authority
HK
Hong Kong
Prior art keywords
antagonist formulations
antagonist
formulations
Prior art date
Application number
HK07110745.0A
Other languages
English (en)
Inventor
Daniel Dix
Katherine Bowers
Goolcharran Chimanlall
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1105421A1 publication Critical patent/HK1105421A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK07110745.0A 2004-08-17 2007-10-04 Il-1 antagonist formulations il-1 HK1105421A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60213704P 2004-08-17 2004-08-17
PCT/US2005/029428 WO2006023665A2 (fr) 2004-08-17 2005-08-17 Formulations d'un antagoniste il-1

Publications (1)

Publication Number Publication Date
HK1105421A1 true HK1105421A1 (en) 2008-02-15

Family

ID=35968186

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110745.0A HK1105421A1 (en) 2004-08-17 2007-10-04 Il-1 antagonist formulations il-1

Country Status (15)

Country Link
US (1) US7365165B2 (fr)
EP (2) EP2311871A3 (fr)
JP (2) JP4948410B2 (fr)
CN (1) CN101014617B (fr)
AU (1) AU2005277357B2 (fr)
BR (1) BRPI0514411B8 (fr)
CA (1) CA2576519C (fr)
DK (1) DK1778723T3 (fr)
ES (1) ES2395035T3 (fr)
HK (1) HK1105421A1 (fr)
PL (1) PL1778723T3 (fr)
PT (1) PT1778723E (fr)
SI (1) SI1778723T1 (fr)
WO (1) WO2006023665A2 (fr)
ZA (1) ZA200701529B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
CA2687246A1 (fr) * 2007-06-01 2008-12-11 Acologix, Inc. Formulation de peptide stable a haute temperature
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
EP2598526B1 (fr) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Agonistes et antagonistes chimeriques du recepteur d'il-1 type i
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CN103957898B (zh) 2011-11-18 2016-02-24 瑞泽恩制药公司 聚合物蛋白微粒
TW201611843A (en) * 2012-04-04 2016-04-01 Polaris Group Methods of treatment with arginine deiminase
WO2014035361A1 (fr) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) Composition d'inhibiteur de l'il-1β et son utilisation
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
EP2991672A1 (fr) 2013-04-30 2016-03-09 Novo Nordisk A/S Schéma d'administration d'un nouveau type
RU2744630C2 (ru) 2016-09-16 2021-03-12 Льюкокэар Аг Новый способ стабилизации биофармацевтического лекарственного продукта при производстве
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
WO1996024369A1 (fr) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations de preparation d'interleukine-12
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4172842B2 (ja) * 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
ES2338218T3 (es) * 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
PT1589949E (pt) * 2003-01-08 2008-11-06 Novartis Vaccines & Diagnostic Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares

Also Published As

Publication number Publication date
EP2311871A2 (fr) 2011-04-20
AU2005277357B2 (en) 2011-08-04
JP2008510716A (ja) 2008-04-10
US20060040852A1 (en) 2006-02-23
EP2311871A3 (fr) 2012-08-08
WO2006023665A3 (fr) 2006-08-03
WO2006023665A2 (fr) 2006-03-02
JP2012121894A (ja) 2012-06-28
EP1778723B1 (fr) 2012-11-14
BRPI0514411A (pt) 2008-06-10
US7365165B2 (en) 2008-04-29
JP4948410B2 (ja) 2012-06-06
CA2576519A1 (fr) 2006-03-02
BRPI0514411B8 (pt) 2021-05-25
CA2576519C (fr) 2013-05-21
DK1778723T3 (da) 2012-12-03
CN101014617B (zh) 2011-03-30
ZA200701529B (en) 2008-09-25
CN101014617A (zh) 2007-08-08
SI1778723T1 (sl) 2013-02-28
PL1778723T3 (pl) 2013-03-29
BRPI0514411B1 (pt) 2020-09-15
ES2395035T3 (es) 2013-02-07
EP1778723A2 (fr) 2007-05-02
PT1778723E (pt) 2013-01-25
AU2005277357A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
HK1105421A1 (en) Il-1 antagonist formulations il-1
IL237756A0 (en) Antibody compositions
IL227215A (en) Vegf antagonists
EP1825866A4 (fr) Preparation solide
GB0423565D0 (en) Formulation
EP1712218A4 (fr) Preparation de teinture capillaire
GB0412530D0 (en) Formulation
GB0506035D0 (en) Improved formulation
ZA200606977B (en) Alkaloid formulations
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
IL179208A0 (en) Intereferon formulations
GB0409607D0 (en) Antagonist
GB0408112D0 (en) Improved formulation
GB0407958D0 (en) Formulation
GB0426142D0 (en) Formulation
GB0401114D0 (en) Formulation
GB0427248D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0426295D0 (en) Novel formulations
GB0420817D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0426294D0 (en) Novel formulations
GB0426293D0 (en) Novel formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220822